gamma-amino butyric acid type a receptor mutations at beta2n265 alter etomidate efficacy while preserving basal and agonist-dependent activity.  etomidate acts at  xxxd2177xxx  type a (gabaa) receptors containing  xxxg837xxx   xxxg1553xxx   xxxg2356xxx  or  xxxg838xxx , but not  xxxg836xxx  subunits. mutations at beta residue 265 (ser in  xxxg836xxx ; asn in  xxxg837xxx   xxxg1553xxx   xxxg2356xxx  or  xxxg838xxx ) profoundly affect etomidate sensitivity. whether these mutations alter etomidate binding remains uncertain.